STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)

Vladmir C. Cordeiro de Lima, Marcelo Corassa, Erick Saldanha, Helano Freitas, Oscar Arrieta, Luis Raez, Suraj Samtani, Maritza Ramos, Carlos Rojas, Mauricio Burotto, Diego F. Chamorro, Gonzalo Recondo, Alejandro Ruiz-Patiño, Luis Más, Lucia Zatarain-Barrón, Sergio Mejía, José Nicolas Minata, Claudio Martín, Juan Bautista Blaquier, Rodrigo Motta GuerreroCarlos Aliaga-Macha, Carlos Carracedo, Camila Ordóñez-Reyes, Juan Esteban Garcia-Robledo, Luis Corrales, Carolina Sotelo, Luisa Ricaurte, Nicolas Santoyo, Mauricio Cuello, Elvira Jaller, July Rodríguez, Pilar Archila, Maritza Bermudez, Tatiana Gamez, Alessandro Russo, Lucia Viola, Umberto Malapelle, Diego de Miguel Perez, Christian Rolfo, Rafael Rosell, Andrés F. Cardona*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Mutations in STK11 (STK11Mut) and, frequently co-occurring, KEAP1 mutations (KEAP1Mut) are associated with poor survival in metastatic Non-small Cell Lung Cancer (mNSCLC) patients treated with immunotherapy. However, there are limited data regarding the prognostic or predictive significance of these genomic alterations among Hispanics. Methods: This retrospective study analyzed a cohort of Hispanic patients (N = 103) diagnosed with mNSCLC from the US and seven Latin American countries (LATAM) treated with immune checkpoint inhibitors (ICI) alone or in combination as first-line (Cohort A). All cases were treated in routine care between January 2016 and December 2021. The main objectives were to determine the association of mutations in STK11 or KEAP1 in these patients’ tumors with overall (OS) and progression-free survival (PFS), presence of KRAS mutations, tumor mutational burden (TMB), and other relevant clinical variables. To compare outcomes with a STK11Wt/KEAP1Wt population, historical data from a cohort of Hispanic patients (N = 101) treated with first-line ICI was used, matching both groups by country of origin, gender, and Programed Death-ligand 1 (PD-L1) expression level (Cohort B). Results: Most tumors had mutations only in STK11 or KEAP1 (45.6%) without KRAS co-mutation or any other genomic alteration. Besides, 35%, 8.7%, 6.8%, and 3.9% were KRASMut + STK11Mut, KRASMut + STK11Mut + KEAP1Mut, STK11Mut + KEAP1Mut, and KRASMut + KEAP1Mut, respectively. Based on KRAS status, STK11 alterations were associated with significantly lower PD-L1 expression among those with KRASWt (p = 0.023), whereas KEAP1 mutations were predominantly associated with lower PD-L1 expression among KRASMut cases (p = 0.047). Tumors with KRASMut + KEAP1Mut had significantly higher median TMB when compared to other tumors (p = 0.040). For Cohort A, median PFS was 4.9 months (95%CI 4.3–5.4), slightly longer in those with KEAP1mut 6.1 months versus STK11Mut 4.7 months (p = 0.38). In the same cohort, PD-L1 expression and TMB did not influence PFS. OS was significantly longer among patients with tumors with PD-L1 ≥ 50% (30.9 months), and different from those with PD-L1 1–49% (22.0 months), and PD-L1 < 1% (12.0 months) (p = 0.0001). When we compared the cohorts A and B, OS was significantly shorter for patients carrying STK1 [STK11Mut 14.2 months versus STK11Wt 27.0 months (p = 0.0001)] or KEAP1 [KEAP1Mut 12.0 months versus KEAP1Wt 24.4 months (p = 0.005)] mutations. PD-L1 expression significantly affected OS independently of the presence of mutations in STK11, KEAP1, or KRAS. TMB-H favored better OS. Conclusions: This is the first large Hispanic cohort to study the impact of STK11 and KEAP1 mutations in NSCLC patient treated with ICI. Our data suggest that mutations in the above-mentioned genes are associated with PD-L1 expression levels and poor OS.

Original languageEnglish
Pages (from-to)114-121
Number of pages8
JournalLung Cancer
Volume170
DOIs
StatePublished - Aug 2022
Externally publishedYes

Bibliographical note

Funding Information:
AC discloses financial research support from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myer Squibb, and The Foundation for Clinical and Applied Cancer Research – FICMAC. Additionally, he was linked and received honoraria as an advisor, participated in speakers’ bureau, and gave expert testimony to Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly, and Foundation for Clinical and Applied Cancer Research – FICMAC. OA reports personal fees from Pfizer, grants and individual fees from Astra Zeneca, grants and individual fees from Boehringer-Ingelheim, personal fees from Lilly, individual fees from Merck, and personal fees from Bristol Myers Squibb, grants and personal fees from Roche, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher Copyright:
© 2022 The Authors

Keywords

  • Hispanics
  • Immunotherapy
  • KEAP1
  • Non-small cell lung cancer
  • STK11
  • Survival

Fingerprint

Dive into the research topics of 'STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)'. Together they form a unique fingerprint.

Cite this